Discovery of a potential allosteric ligand binding site in CDK2.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  ACS Chemical Biology

• Publication date

  2011-05-20

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/cb100410mPMID 21291269PMCID PMC3098941
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases.

  2011cited by this paper
• Through the "gatekeeper door": exploiting the active kinase conformation.

  2010cited by this paper
• Displacement assay for the detection of stabilizers of inactive kinase conformations.

  2010cited by this paper
• Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations.

  2010cited by this paper
• Recent developments in cyclin-dependent kinase biochemical and structural studies.

  2010cited by this paper
• Targeting cancer with small molecule kinase inhibitors

  2009cited by this paper
• Truncation and Optimisation of Peptide Inhibitors of Cyclin‐Dependent Kinase 2‐Cyclin A Through Structure‐Guided Design

  2009cited by this paper
• Protein kinase inhibitors: contributions from structure to clinical compounds

  2009cited by this paper
• Identifying allosteric fluctuation transitions between different protein conformational states as applied to Cyclin Dependent Kinase 2

  2007cited by this paper
• The selectivity of protein kinase inhibitors: a further update.

  2007cited by this paper
• The Role of the Phospho-CDK2/Cyclin A Recruitment Site in Substrate Recognition*

  2006cited by this paper
• Rational design of inhibitors that bind to inactive kinase conformations

  2006cited by this paper
• Design of a Novel Class of Peptide Inhibitors of Cyclin-dependent Kinase/Cyclin Activation*

  2005cited by this paper
• The Retinoblastoma Protein and Cell Cycle Control Review

  2004cited by this paper
• Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

  2004cited by this paper
• Coot: model-building tools for molecular graphics.

  2004cited by this paper
• Substrate Specificity of CDK2-Cyclin A

  2003cited by this paper
• Selective cyclin-dependent kinase 2/cyclin A antagonists that differ from ATP site inhibitors block tumor growth.

  2003cited by this paper
• Peptidomimetic design of CDK inhibitors targeting the recruitment site of the cyclin subunit.

  2003cited by this paper
• Cyclin D-dependent kinases, INK4 inhibitors and cancer.

  2002cited by this paper
• Kinetic Mechanism of Activation of the Cdk2/Cyclin A Complex

  2002cited by this paper
• Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

  2002cited by this paper
• The PyMOL Molecular Graphics System

  2002cited by this paper
• To cycle or not to cycle: a critical decision in cancer

  2001cited by this paper
• Structural basis for the interaction of the fluorescence probe 8-anilino-1-naphthalene sulfonate (ANS) with the antibiotic target MurA.

  2000cited by this paper
• Effects of Phosphorylation of Threonine 160 on Cyclin-dependent Kinase 2 Structure and Activity*

  1999cited by this paper
• Crystallography & NMR system: A new software suite for macromolecular structure determination.

  1998cited by this paper
• Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2

  1997cited by this paper
• Interactions of cyclins with cyclin-dependent kinases: a common interactive mechanism.

  1997cited by this paper
• Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer.

  1996cited by this paper
• Cancer Cell Cycles

  1996cited by this paper
• Crystal structure of the p27Kip1 cyclin-dependent-kinase inibitor bound to the cyclin A–Cdk2 complex

  1996cited by this paper
• Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs).

  1995cited by this paper
• Principles of CDK regulation

  1995cited by this paper
• Phosphorylation modulates catalytic function and regulation in the cAMP-dependent protein kinase.

  1995cited by this paper
• The retinoblastoma protein and cell cycle control.

  1995cited by this paper
• Distinct roles for cyclin-dependent kinases in cell cycle control.

  1993cited by this paper
• Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants

  1993cited by this paper
• Molecular oncology

  1991cited by this paper
• Improved methods for building protein models in electron density maps and the location of errors in these models.

  1991cited by this paper
• Assessment of inner filter effect corrections in fluorimetry

  1991cited by this paper
• Adenosine cyclic 3',5'-monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit.

  1982cited by this paper
• 2,4-Diamino-6-phenyl-1,3,5-triazines

  1978cited by this paper
• The interaction of a naphthalene dye with apomyoglobin and apohemoglobin. A fluorescent probe of non-polar binding sites.

  1965cited by this paper
• FRAGMENTATION OF BOVINE SERUM ALBUMIN BY PEPSIN. I. THE ORIGIN OF THE ACID EXPANSION OF THE ALBUMIN MOLECULE.

  1964cited by this paper
• Biological Crystallography Structural Biology Contributions to the Discovery of Drugs to Treat Chronic Myelogenous Leukaemia

  year unknowncited by this paper

• CDK2 Allosteric Modulators: The New Route in the Design of New Drugs as Anticancer and Non-hormonal Contraceptives.

  2025cites this paper
• Molecular dynamics simulations of proteins: an in-depth review of computational strategies, structural insights, and their role in medicinal chemistry and drug development

  2025cites this paper
• Structural, Electronic, and Molecular Dynamics Perspectives of Andrographolides as Potential CDK2 Inhibitors

  2025cites this paper
• Markovian state models uncover casein kinase 1 dynamics that govern circadian period

  2025cites this paper
• Structural analysis of 8-anilino-1-naphthalene sulfonate (ANS) binding to the PR-10 allergen Ara h 8.

  2025cites this paper
• Unravelling phosphorylation-induced impacts on inhibitor-CDK2 through multiple independent molecular dynamics simulations and deep learning

  2025cites this paper
• Discovery of AZD8421: A Potent CDK2 Inhibitor with Selectivity Against Other CDK Family Members and the Human Kinome.

  2025cites this paper
• Targeting CDK2 for cancer therapy

  2025cites this paper
• Allosteric inhibitors for the treatment of cancers (2021-): A review from medicinal chemistry perspectives

  2025cites this paper
• Structure-Based Design of Potent and Selective MerTK Inhibitors by Modulating the Conformation of αC Helix

  2025cites this paper
• Computational and Experimental Insights into Azo-Containing Aroylhydrazones: A Promising Class of CDK2 Inhibitors

  2025cites this paper
• Can Deep Learning Blind Docking Methods be Used to Predict Allosteric Compounds?

  2025cites this paper
• Going beyond ATP binding site as a novel inhibitor design strategy for tau protein kinases in the treatment of alzheimer's disease: A review.

  2025cites this paper
• FeatureDock for protein-ligand docking guided by physicochemical feature-based local environment learning using transformer

  2025cites this paper
• Targeting cyclin-dependent kinase 2 (CDK2) interactions with cyclins and Speedy 1 (Spy1) for cancer and male contraception.

  2025cites this paper
• Lucidin from Rubia cordifolia Outperforms FDA-Approved Lapatinib as a Potential Multitargeted Candidate for Breast Cancer Signalling Proteins

  2025cites this paper
• Targeting cyclin-dependent kinases: From pocket specificity to drug selectivity.

  2024cites this paper
• Discovering new CDK2 inhibitors by molecular docking and drug-likeness-based virtual screening for potential anticancer uses.

  2024cites this paper
• Cdk6’s functions are critically regulated by its unique C-terminus

  2024cites this paper
• Binding Modalities and Phase-Specific Regulation of Cyclin/Cyclin-Dependent Kinase Complexes in the Cell Cycle.

  2024cites this paper
• Predicting Inhibition of CDK2 with SAnDReS: The Application of Machine Learning to Navigate the Scoring Function Space.

  2024cites this paper
• Inhibitors and PROTACs of CDK2: challenges and opportunities

  2024cites this paper
• Slower CDK4 and faster CDK2 activation in the cell cycle.

  2024cites this paper
• Allosteric regulation and inhibition of protein kinases.

  2023cites this paper
• Recent Development of CDK2 Inhibitors as Anticancer Drugs: An Update (2015–2023)

  2023cites this paper
• Synthesis, Structure, and In Vitro Pharmacological Evaluation of some New Pyrimidine-2-Sulfonamide Derivatives and Their Molecular Docking Studies on Human Estrogen Receptor Alpha and CDK2/Cyclin Proteins

  2023cites this paper
• Unraveling the unexpected aggregation behavior of Pyrazole-Based compounds Targeting Mycobacterium tuberculosis UDP-Galactopyranose mutase.

  2023cites this paper
• Cell cycle progression mechanisms: slower cyclin-D/CDK4 activation and faster cyclin-E/CDK2

  2023cites this paper
• LifeSoaks: a tool for analyzing solvent channels in protein crystals and obstacles for soaking experiments

  2023cites this paper
• Polyethylene Glycol as a Green Medium for the Microwave‐Assisted Synthesis of Guanamines

  2023cites this paper
• Screening through Lead Optimization of High Affinity, Allosteric Cyclin-Dependent Kinase 2 (CDK2) Inhibitors as Male Contraceptives That Reduce Sperm Counts in Mice.

  2023cites this paper
• Targeting the binding pocket of the fluorophore 8‐anilinonaphthalene‐1‐sulfonic acid in the bacterial enzyme MurA

  2023cites this paper
• Development of allosteric and selective CDK2 inhibitors for contraception with negative cooperativity to cyclin binding

  2023cites this paper
• Research and Evaluation of the Allosteric Protein-Specific Force Field Based on a Pre-Training Deep Learning Model

  2023cites this paper
• Utilization of kinase inhibitors as novel therapeutic drug targets: A review

  2023cites this paper
• Ensemble learning from ensemble docking: revisiting the optimum ensemble size problem

  2022cites this paper
• Emerging approaches to CDK inhibitor development, a structural perspective

  2022cites this paper
• Crystal structure of the CDK11 kinase domain bound to the small-molecule inhibitor OTS964.

  2022cites this paper
• Hydrogen Sulfide Promotes Adipocyte Differentiation, Hyperplasia, and Hypertrophy

  2022cites this paper
• Identification of natural marine compounds as potential inhibitors of CDK2 using molecular docking and molecular dynamics simulation approach

  2022cites this paper
• Structure-guided design and development of cyclin-dependent kinase 4/6 inhibitors: A review on therapeutic implications.

  2022cites this paper
• Expression of the cyclin-dependent kinase 2 gene (cdk2) influences ovarian development in the ridgetail white prawn, Exopalaemon carinicauda

  2022cites this paper
• Prediction of allosteric druggable pockets of cyclin-dependent kinases

  2022cites this paper
• Development of allosteric, selective cyclin-dependent kinase 2 (CDK2) inhibitors that are negatively cooperative with cyclin binding and show potential as contraceptive agents

  2022cites this paper
• Principles of Kinase Allosteric Inhibition and Pocket Validation.

  2022cites this paper
• Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts.

  2022cites this paper
• Dynamics of Post-Translational Modification Inspires Drug Design in the Kinase Family.

  2021cites this paper
• A molecular perspective for the use of type IV tyrosine kinase inhibitors as anticancer therapeutics.

  2021cites this paper
• Cyclin-dependent kinases as therapeutic targets

  2021cites this paper
• Molecular mechanism concerning conformational changes of CDK2 mediated by binding of inhibitors using molecular dynamics simulations and principal component analysis

  2021cites this paper
• Allosteric Type and Pathways Are Governed by the Forces of Protein-Ligand Binding.

  2021cites this paper
• Design and Discovery of Kinase Inhibitors Using Docking Studies

  2021cites this paper
• GOLEM: Automated and Robust Cryo-EM-Guided Ligand Docking with Explicit Water Molecules

  2021cites this paper
• Inhibitors of Cyclin-Dependent Kinases: Types and Their Mechanism of Action

  2021cites this paper
• Identification of selective cyclin-dependent kinase 2 inhibitor from the library of pyrrolone-fused benzosuberene compounds: an in silico exploration

  2021cites this paper
• Tetrahydroindazole inhibitors of CDK2/cyclin complexes.

  2021cites this paper
• Development of CDK2 and CDK5 Dual Degrader TMX-2172.

  2020cites this paper
• Exploring ligand binding pathways on proteins using hypersound-accelerated molecular dynamics

  2020cites this paper
• Inhibitors of Cyclin-Dependent Kinase 1/2 for Anticancer Treatment.

  2020cites this paper
• The Cytomegalovirus Protein Kinase pUL97: Host Interactions, Regulatory Mechanisms and Antiviral Drug Targeting

  2020cites this paper
• How does evolution design functional free energy landscapes of proteins? A case study on the emergence of regulation in the Cyclin Dependent Kinase family

  2020cites this paper
• ANS Interacts with the Ca2+-ATPase Nucleotide Binding Site

  2020cites this paper
• In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs

  2020cites this paper
• nAPOLI: A Graph-Based Strategy to Detect and Visualize Conserved Protein-Ligand Interactions in Large-Scale

  2020cites this paper
• Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations

  2020cites this paper
• Identification of druggable kinase target conformations using Markov model metastable states analysis of apo Abl.

  2020cites this paper
• Identification and characterization of fragment binding sites for allosteric ligand design using the site identification by ligand competitive saturation hotspots approach (SILCS-Hotspots).

  2020cites this paper
• Computational Analysis of Crystallization Additives for the Identification of New Allosteric Sites

  2020cites this paper
• Cyclin-Dependent Kinase as a Novel Therapeutic Target: An Endless Story

  2020cites this paper
• The promise and current status of CDK12/13 inhibition for the treatment of cancer.

  2020cites this paper
• Dimeric Structure of the Pseudokinase IRAK3 Suggests an Allosteric Mechanism for Negative Regulation

  2020cites this paper
• Avoiding or Co-Opting ATP Inhibition: Overview of Type III, IV, V, and VI Kinase Inhibitors

  2020cites this paper
• Next Generation Kinase Inhibitors: Moving Beyond the ATP Binding/Catalytic Sites

  2020cites this paper
• Review of rationale and progress toward targeting cyclin-dependent kinase 2 (CDK2) for male contraception†

  2020cites this paper
• Function, Structure and Topology of Protein Kinases

  2020cites this paper
• Cooperativity Between Orthosteric Inhibitors and Allosteric Inhibitor 8-Anilino-1-Naphthalene Sulfonic Acid (ANS) in Cyclin-Dependent Kinase 2.

  2020cites this paper
• Tuning the “violin” of protein kinases: The role of dynamics‐based allostery

  2019cites this paper
• Differences in the Conformational Energy Landscape of CDK1 and CDK2 Suggest a Mechanism for Achieving Selective CDK Inhibition

  2019cites this paper
• Recent development of CDK inhibitors: An overview of CDK/inhibitor co-crystal structures.

  2019cites this paper
• Allosteric Modulator Discovery: From Serendipity to Structure-Based Design.

  2019cites this paper
• FragLites-Minimal, Halogenated Fragments Displaying Pharmacophore Doublets. An Efficient Approach to Druggability Assessment and Hit Generation.

  2019cites this paper
• Deactivation Pathway of Ras GTPase Underlies Conformational Substates as Targets for Drug Design

  2019cites this paper
• Protein Allostery in Rational Drug Design.

  2019cites this paper
• Interrogating Regulatory Mechanisms in Signaling Proteins by Allosteric Inhibitors and Activators: A Dynamic View Through the Lens of Residue Interaction Networks.

  2019cites this paper
• Characteristics of Allosteric Proteins, Sites, and Modulators.

  2019cites this paper
• Identification of novel CDK2 inhibitors by a multistage virtual screening method based on SVM, pharmacophore and docking model

  2019cites this paper
• Rational drug design, synthesis, and biological evaluation of novel chiral tetrahydronaphthalene-fused spirooxindole as MDM2-CDK4 dual inhibitor against glioblastoma

  2019cites this paper
• Structure-based discovery and development of cyclin-dependent protein kinase inhibitors

  2018cites this paper
• Effect of Substituents in Different Positions of Aminothiazole Hinge-Binding Scaffolds on Inhibitor–CDK2 Association Probed by Interaction Entropy Method

  2018cites this paper
• Concestor kinase activation mechanism uncovers the cyclin dependence of CDK family kinases

  2018influential citation
• Using molecular simulation to explore the nanoscale dynamics of the plant kinome.

  2018cites this paper
• Cyclin-Dependent Kinase 2 Inhibitors in Cancer Therapy: An Update.

  2018cites this paper
• Overview of Current Type I/II Kinase Inhibitors

  2018cites this paper
• Design of Tat-Activated Cdk9 Inhibitor

  2018influential citation
• Recent advances in CDK inhibitors for cancer therapy.

  2018cites this paper
• High‐Throughput Kinetic Analysis for Target‐Directed Covalent Ligand Discovery

  2018cites this paper
• The Role Of Cdk8 In Metastatic Growth Of Colon Cancer

  2018cites this paper
• Exploration and Comparison of the Geometrical and Physicochemical Properties of an αC Allosteric Pocket in the Structural Kinome

  2018cites this paper
• Predicting Protein Dynamics and Allostery Using Multi-Protein Atomic Distance Constraints

  2017cites this paper
• Structure-based discovery of cyclin-dependent protein kinase inhibitors.

  2017cites this paper